Jump to main content
Jump to site search

Issue 22, 2016
Previous Article Next Article

Synthesis of amino heterocycle aspartyl protease inhibitors

Author affiliations

Abstract

Aspartyl proteases are important pharmacological targets. Historically aspartyl proteases have been commonly targeted with transition state derived peptidomimetics. The strategy to develop aspartyl protease inhibitors has undertaken a dramatic paradigm shift in the last 10 years. The pharmaceutical industry in 2005 disclosed several scaffolds or “head groups” that prompted the field to move beyond peptidomimetic derived inhibitors. Since the discovery of the first amino heterocycle aspartyl protease inhibitor, the amino hydantoin, industry and academia have positioned themselves for a foothold on the new molecular space, designing a variety of related “head groups”. Both the design and synthetic efforts involved in constructing these scaffolds are varied and complex. Here we highlight the synthetic strategies used to access these amino heterocycle scaffolds.

Graphical abstract: Synthesis of amino heterocycle aspartyl protease inhibitors

Back to tab navigation

Article information


Submitted
05 Mar 2016
Accepted
21 Apr 2016
First published
28 Apr 2016

Org. Biomol. Chem., 2016,14, 4970-4985
Article type
Review Article
Author version available

Synthesis of amino heterocycle aspartyl protease inhibitors

R. K. Chambers, T. A. Khan, D. B. Olsen and B. E. Sleebs, Org. Biomol. Chem., 2016, 14, 4970
DOI: 10.1039/C5OB01842K

Social activity

Search articles by author

Spotlight

Advertisements